| 122.48 Delayed Data As of Feb 15 |  +1.73 / +1.43%Today’s Change | 74.51 Today|||52-Week Range 122.48 | +5.84% Year-to-Date |
| Previous close | 120.75 |
| Today’s open | 121.18 |
| Day’s range | 120.40 - 122.48 |
| Volume | 10,366,435 |
| Average volume (3 months) | 5,421,615 |
| Market cap | $129.7B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +0.77% |
| Earnings growth (next 5 years) | +11.00% |
| Revenue growth (last year) | +7.36% |
| P/E ratio | 260.6 |
| Price/Sales | 4.87 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| ABTAbbott Laboratories | +1.28 | +1.73% |
| SNYSanofi | +0.99 | +2.38% |
| ABBVAbbVie | +0.33 | +0.41% |
| AZNAstraZeneca | +0.94 | +2.35% |
| Next reporting date | April 30, 2019 |
| EPS forecast (this quarter) | $1.37 |
| Annual revenue (last year) | $24.6B |
| Annual profit (last year) | $3.2B |
| Net profit margin | 13.16% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer David A. Ricks |
Senior VP-Biotechnology & Autoimmunity Research Thomas F. Bumol |
Corporate headquarters Indianapolis, Indiana |
